Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...

Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the ...

Bank of America raised AbbVie’s price target from $200 to $223 while maintaining a neutral rating. Other analysts have also ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report released on Monday, ...

Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...

In a report released on March 2, David Risinger from Leerink Partners maintained a Hold rating on Amgen (AMGN – Research Report). The company’s ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

The Financial Times is reporting that Walgreens Boots Alliance would be split three ways if Sycamore Partners buys out the ...

A live webcast link for the Leerink Partners Global Biopharma Conference fireside chat will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be ...

A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s ...

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...